Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Lung Cancer Clinical Trial

Official title:

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05401110
• Other study ID #: IIT2021-12-Reckamp-Osi105
• Status: Recruiting
• Phase: Phase 1
• Start date: September 15, 2023
• Est. completion date: January 2026

Study information

• Verified date: April 2024
• Source: Cedars-Sinai Medical Center
• Contact: Clinical Trial Recruitment Navigator
• Phone: 310-423-2133
• Email: cancer.trial.info[@]cshs.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: January 2026
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Stage IV or recurrent/metastatic non-squamous NSCLC that harbors an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q, etc). Local testing for EGFR mutations is acceptable provided it was performed in a CLIA certified lab.
• Part I: Progressive disease on at least one prior EGFR TKI
• Part II, Cohort 1: Progressive disease on osimertinib or other prior EGFR TKIs
• Part II, Cohort 2: Receiving osimertinib as front line treatment for less than 12 weeks. Persistent ctDNA with EGFR mutation between weeks 6-12 from the start of osimertinib treatment.
• Age at least 18
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2
• Archival tissue from a biopsy performed after progression of disease on previous EGFR TKI or willing to consent for a fresh tumor biopsy.
• Measurable disease by RECIST 1.1.
• Patients with untreated brain metastases are allowed provided that the patient is clinically asymptomatic and stable.
• Patients must have completed prior chemotherapy = 3 weeks or radiotherapy = 2 weeks prior to receiving study drugs.
• If the subject's most recent line of therapy is treatment with osimertinib, then all adverse events must be resolved to Grade 2 or better
• If the subject's most recent line of therapy is any other treatment than osimertinib, then all Adverse Events must be resolved to grade 1 or better, with the exception of fatigue, alopecia and neuropathy (which must resolve to CTCAE grade 2).
• Adequate organ function
• Women of childbearing potential and men must agree to use adequate contraception while on study.
• Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

• Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease.
• Small cell lung cancer histology.
• Other prior malignancy that might interfere with study endpoints per opinion of the investigator.
• Prior exposure to carotuximab or any CD105 targeted antibody.
• Any major surgical procedure within 2 weeks of starting therapy.
• Patients must not have a history of uncontrolled or poorly-controlled hypertension defined as SBP > 150 mmHg or DBP > 90 mmHg within 28 days prior to enrollment.
• Active bleeding or pathologic conditions that carries a high bleeding risk (e.g. gastric ulcers).
• Use of thrombolytics within 10 days prior to the first day of carotuximab.
• Known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies.
• A known diagnosis of Osler-Weber-Rendu syndrome.
• Ascites or pericardial or pleural effusion requiring external drainage procedures.
• New evidence of leptomeningeal disease.
• Acute cardiovascular event within the past 6 months.
• Pregnancy or breastfeeding.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Cancer
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• Osimertinib
Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
• Carotuximab
Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.

Locations

Country	Name	City	State
United States	Cedars-Sinai Cancer at Beverly Hills (THO)	Beverly Hills	California
United States	Cedars-Sinai Cancer at SOCC	Los Angeles	California
United States	Cedars-Sinai Cancer at The Angeles Clinic and Research Institute	Los Angeles	California
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC	Torrance	California

Sponsors (2)

Lead Sponsor	Collaborator
Karen Reckamp, MD, MS	Enviro Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of adverse events and dose-limiting toxicities to find the Recommended Phase 2 Dose (RP2D) of combination of osimertinib with carotuximab in treatment of advanced, EGFR-mutated non-small cell lung cancer.	The number of adverse events are graded by NCI CTCAE v5.0. The number of these dose-limiting toxicities (DLTs) experienced within the first treatment cycle (28 days) will be assessed to determine the RP2D.	4 weeks
Secondary	Objective response rate	Proportion of participants with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1.	Assessed from baseline until the date of first documented progression, which is the end of treatment (EOT), assessed up to 2 years.
Secondary	Disease control rate	Proportion of participants with confirmed CR, PR, or stable disease (SD) per RECIST v.1.1	Assessed from baseline until EOT, up to 2 years.
Secondary	Duration of response	Length of time from treatment response to progressive disease (PD) per RECIST v.1.1or death.	From baseline to first documentation of PD or death, whichever came first. Assessed up to 2 years.
Secondary	Progression free survival.	From Cycle 1 Day 1 (C1D1) until first documentation of PD per RECIST v.1.1 or death due to any cause.	Assessed from the time of treatment initiation (C1D1) until first documentation of progression, or death due to any cause, whichever came first. Assessed up to 2 years. One treatment cycle is 28 days.
Secondary	Biomarkers using tumor tissue and serial ctDNA for mutations.	ctDNA will be evaluated for genomic alterations.	From baseline until disease progression, or death, whichever came first. Assessed up to 2 years.
Secondary	Biomarkers of response to the combination using tumor tissue and serial ctDNA.	ctDNA will be evaluated to correlate with response.	From baseline until disease progression, or death, whichever came first. Assessed up to 2 years.